Browsing Institutt for helse og samfunn by Author "Mørk, Cato"

Now showing items 1-2 of 2

  • Improvement in Psoriasis Area and Severity Index Score predicts improvement in skin pain over time in patients with psoriasis 
    Ljoså, Tone Marte; Stubhaug, Audun; Mørk, Cato; Moum, Torbjørn Åge; Wahl, Astrid Klopstad (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2013)
    Pain and discomfort are common and often severe skin symptoms in patients with psoriasis. However, no studies have investigated skin pain and discomfort over time, or factors that explain changes in these symptoms. The ...
  • Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: Open‐label extension of the NOR‐SWITCH trial 
    Goll, Guro Løvik; Jørgensen, Kristin Kaasen; Sexton, Joseph; Olsen, Inge Christoffer; Bolstad, Nils; Haavardsholm, Espen A.; Lundin, Knut Erik Aslaksen; Tveit, Kåre Steinar; Lorentzen, Merete; Berset, Ingrid Prytz; Fevang, Bjørg-Tilde Svanes; Kalstad, Synnøve; Ryggen, Kristin; Warren, David; Klaasen, Rolf; Asak, Øivind Wessel; Baigh, Somyeh; Blomgren, Ingrid; Brenna, Øystein; Bruun, Trude J; Dvergsnes, Katrine; Frigstad, Svein Oskar; Myrnes, Inger; Hatten, Ingvild Helgheim; Huppertz-Hauss, Gert; Henriksen, Magne; Hoie, Sunniva S.; Krogh, Jan Reidar; Midtgard, Irina P.; Mielnik, Pawel; Moum, Bjørn; Noraberg, Geir; Poyan, Armin; Prestegård, Ulf; Rashid, Haroon Ur; Strand, Eldri Kveine; Skjetne, Kristine; Seeberg, Kathrine; Torp, Roald; Ystrøm, Carl Magnus; Vold, Cecilia; Zettel, Camilla C.; Waksvik, Kenneth; Gulbrandsen, Bjørn; Hagfors, Jon; Mørk, Cato; Jahnsen, Jørgen; Kvien, Tore Kristian (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2019)
    Background and objectives The 52‐week, randomized, double‐blind, noninferiority, government‐funded NOR‐SWITCH trial demonstrated that switching from infliximab originator to less expensive biosimilar CT‐P13 was not ...